Stroke PreventionAtrial Fibrillation Treatment Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral Direct Thrombin Inhibitors
1.2.3 Oral Direct Factor Xa Inhibitors
1.3 Market by Application
1.3.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Perspective (2017-2028)
2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Growth Trends by Region
2.2.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Region (2017-2022)
2.2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Region (2023-2028)
2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Dynamics
2.3.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Industry Trends
2.3.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
2.3.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
2.3.4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue
3.1.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue (2017-2022)
3.1.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue
3.4 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio
3.4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2021
3.5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players Head office and Area Served
3.6 Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
3.7 Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Type
4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Type (2017-2022)
4.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2023-2028)
5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Application
5.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Application (2017-2022)
5.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2017-2028)
6.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
6.2.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022)
6.2.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028)
6.2.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2017-2028)
6.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
6.3.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022)
6.3.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028)
6.3.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2017-2028)
6.4 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
6.4.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022)
6.4.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2017-2028)
7.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
7.2.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022)
7.2.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028)
7.2.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2017-2028)
7.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
7.3.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022)
7.3.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028)
7.3.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2017-2028)
7.4 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
7.4.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022)
7.4.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2017-2028)
8.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
8.2.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
8.3.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region
8.4.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2017-2028)
9.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
9.2.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2017-2028)
9.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
9.3.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2017-2028)
9.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
9.4.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2017-2028)
10.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type
10.2.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application
10.3.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country
10.4.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Details
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.1.4 Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.2.4 Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.2.5 Bayer Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.3.4 Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.3.5 Johnson & Johnson Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.4.4 Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.5.4 Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.5.5 Pfizer Recent Developments
11.6 Daiichi-Sankyo
11.6.1 Daiichi-Sankyo Company Details
11.6.2 Daiichi-Sankyo Business Overview
11.6.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.6.4 Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.6.5 Daiichi-Sankyo Recent Developments
11.7 Gilead
11.7.1 Gilead Company Details
11.7.2 Gilead Business Overview
11.7.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.7.4 Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
11.7.5 Gilead Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Oral Direct Thrombin Inhibitors
Table 3. Key Players of Oral Direct Factor Xa Inhibitors
Table 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2017-2022)
Table 8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2023-2028)
Table 10. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Trends
Table 11. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
Table 12. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
Table 13. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
Table 14. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Share by Players (2017-2022)
Table 16. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2021)
Table 17. Ranking of Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
Table 21. Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2017-2022)
Table 25. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2023-2028)
Table 27. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Share by Application (2017-2022)
Table 29. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Share by Application (2023-2028)
Table 31. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 61. Boehringer Ingelheim Company Details
Table 62. Boehringer Ingelheim Business Overview
Table 63. Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 64. Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 65. Boehringer Ingelheim Recent Developments
Table 66. Bayer Company Details
Table 67. Bayer Business Overview
Table 68. Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 69. Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 70. Bayer Recent Developments
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 74. Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 75. Johnson & Johnson Recent Developments
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 79. Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 80. Bristol-Myers Squibb Recent Developments
Table 81. Pfizer Company Details
Table 82. Pfizer Business Overview
Table 83. Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 84. Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 85. Pfizer Recent Developments
Table 86. Daiichi-Sankyo Company Details
Table 87. Daiichi-Sankyo Business Overview
Table 88. Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 89. Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 90. Daiichi-Sankyo Recent Developments
Table 91. Gilead Company Details
Table 92. Gilead Business Overview
Table 93. Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
Table 94. Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022) & (US$ Million)
Table 95. Gilead Recent Developments
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type: 2021 VS 2028
Figure 2. Oral Direct Thrombin Inhibitors Features
Figure 3. Oral Direct Factor Xa Inhibitors Features
Figure 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2021 VS 2028
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Report Years Considered
Figure 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region: 2021 VS 2028
Figure 12. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players in 2021
Figure 13. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2021
Figure 15. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Type (2017-2028)
Figure 17. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Application (2017-2028)
Figure 18. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Country (2017-2028)
Figure 19. United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Type (2017-2028)
Figure 23. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Application (2017-2028)
Figure 24. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Country (2017-2028)
Figure 25. Germany Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Region (2017-2028)
Figure 35. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Country (2017-2028)
Figure 45. Mexico Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Country (2017-2028)
Figure 51. Turkey Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Boehringer Ingelheim Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 55. Bayer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 56. Johnson & Johnson Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 58. Pfizer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 59. Daiichi-Sankyo Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 60. Gilead Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2017-2022)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
